JY
IMRX icon

Jeff Yass’s Immuneering IMRX Stock Holding History

Jeff Yass’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
69,053
-36,454
-35% -$184K ﹤0.01% 10749
2026
Q1 		$556K Sell
105,507
-1,965
-2% -$10.1K ﹤0.01% 9383
2025
Q4 		$707K Buy
+107,472
New +$690K ﹤0.01% 8005
2024
Q3 		– Sell
-88,756
Closed -$114K – 12464
2024
Q2 		$114K Buy
+88,756
New +$146K ﹤0.01% 10927
2024
Q1 		– Sell
-10,603
Closed -$77.9K – 12708
2023
Q4 		$77.9K Buy
+10,603
New +$70.6K ﹤0.01% 11496
2023
Q2 		– Sell
-57,949
Closed -$563K – 12577
2023
Q1 		$563K Buy
57,949
+12,949
+29% +$73.5K ﹤0.01% 8274
2022
Q4 		$218K Buy
+45,000
New +$399K ﹤0.01% 9905

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Jeff Yass's IMRX Position: Q2 2026 in Review

Jeff Yass reduced its Immuneering (IMRX) stake by 35% in Q2 2026, selling an estimated $184K and leaving 69,053 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #10749.

Jeff Yass first reported a position in IMRX in Q4 2022 and has held it in 7 quarters since. The position peaked at $707K in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Jeff Yass held 69,053 shares of Immuneering worth $345K as of Q2 2026.
  • Jeff Yass sold 36,454 Immuneering shares in Q2 2026, an estimated $184K.
  • Immuneering made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10749 holding.
  • Jeff Yass first reported a position in Immuneering in Q4 2022 and has held it in 7 quarters since.
  • Jeff Yass's Immuneering position peaked at $707K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.